-
Je něco špatně v tomto záznamu ?
Ayahuasca: exotická psychoaktivní droga nebo lék budoucnosti?
[Ayahuasca: Exotic psychoactive drug or the medicament of the future?]
Vratislav Hrdina, Vladimír Měrka, Jiří Patočka
Jazyk čeština Země Česko
Typ dokumentu přehledy
- Klíčová slova
- ayahuasca, globalizace, tradiční místní znalosti, využití v medicíně, harmalové alkaloidy,
- MeSH
- Banisteriopsis chemie MeSH
- halucinace MeSH
- halucinogeny farmakokinetika farmakologie MeSH
- kardiovaskulární systém účinky léků MeSH
- LD50 MeSH
- lidé MeSH
- modely u zvířat MeSH
- N,N-dimethyltryptamin MeSH
- rostlinné extrakty farmakokinetika farmakologie MeSH
- serotonin MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
Ayahuasca is a drink made from two plants native to the Amazon, Banisteriopsis caapi and Psychotria viridis, which contain the psychoactive chemicals: harmala alkaloids and dimethyltryptamine (DMT). The drink has long been used by aboriginal populations for its putative spiritual and medicinal benefits in countries such as Brazil, Ecuador and Peru. In the 20th century, ayahuasca spread beyond its native habitat and has been incorporated into syncretistic practices that are being adopted by non-indigenous peoples in modern Western contexts. Ayahuasca‘s globalization in the past few decades has led to a number of legal cases which pit religious freedom against national drug control laws. Two principal constituents of ayahuasca are harmala alkaloids and DMT. These compounds, when ingested in combination, produce a unique biochemical synergy resulting in profound idiosyncratic psychoactive effects. Harmala alkaloids are controlled substances in some countries and DMT is prohibited by international drug control conventions. Therefore relatively little is known about therapeutic use of ayahuasca. This article provides an overview of ayahuasca and explores some of the medical and philosophical implications of contemporary ayahuasca use.
Ayahuasca: Exotic psychoactive drug or the medicament of the future?
Lit.: 48
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10016503
- 003
- CZ-PrNML
- 005
- 20160630093456.0
- 008
- 100815s2010 xr e cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Hrdina, Vratislav, $d 1926-2010 $7 xx0019983
- 245 10
- $a Ayahuasca: exotická psychoaktivní droga nebo lék budoucnosti? / $c Vratislav Hrdina, Vladimír Měrka, Jiří Patočka
- 246 11
- $a Ayahuasca: Exotic psychoactive drug or the medicament of the future?
- 314 __
- $a Emeritní profesor Univerzity obrany, Brno
- 504 __
- $a Lit.: 48
- 520 9_
- $a Ayahuasca is a drink made from two plants native to the Amazon, Banisteriopsis caapi and Psychotria viridis, which contain the psychoactive chemicals: harmala alkaloids and dimethyltryptamine (DMT). The drink has long been used by aboriginal populations for its putative spiritual and medicinal benefits in countries such as Brazil, Ecuador and Peru. In the 20th century, ayahuasca spread beyond its native habitat and has been incorporated into syncretistic practices that are being adopted by non-indigenous peoples in modern Western contexts. Ayahuasca‘s globalization in the past few decades has led to a number of legal cases which pit religious freedom against national drug control laws. Two principal constituents of ayahuasca are harmala alkaloids and DMT. These compounds, when ingested in combination, produce a unique biochemical synergy resulting in profound idiosyncratic psychoactive effects. Harmala alkaloids are controlled substances in some countries and DMT is prohibited by international drug control conventions. Therefore relatively little is known about therapeutic use of ayahuasca. This article provides an overview of ayahuasca and explores some of the medical and philosophical implications of contemporary ayahuasca use.
- 650 _2
- $a Banisteriopsis $x chemie $7 D031581
- 650 _2
- $a halucinogeny $x farmakokinetika $x farmakologie $7 D006213
- 650 _2
- $a rostlinné extrakty $x farmakokinetika $x farmakologie $7 D010936
- 650 _2
- $a kardiovaskulární systém $x účinky léků $7 D002319
- 650 _2
- $a LD50 $7 D007928
- 650 _2
- $a modely u zvířat $7 D023421
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a N,N-dimethyltryptamin $7 D004130
- 650 _2
- $a serotonin $7 D012701
- 650 _2
- $a halucinace $7 D006212
- 653 00
- $a ayahuasca
- 653 00
- $a globalizace
- 653 00
- $a tradiční místní znalosti
- 653 00
- $a využití v medicíně
- 653 00
- $a harmalové alkaloidy
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Měrka, Vladimír, $d 1924-2016 $7 jk01081287
- 700 1_
- $a Patočka, Jiří, $d 1939- $7 jn20000401939
- 773 0_
- $w MED00011067 $t Psychiatrie $g Roč. 14, č. 2 (2010), s. 80-84 $x 1211-7579
- 856 41
- $u http://www.tigis.cz/images/stories/psychiatrie/2010/02/05_hrdina_2_2010.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2070 $c 603 a $y 8 $z 0
- 990 __
- $a 20100731105943 $b ABA008
- 991 __
- $a 20160630093644 $b ABA008
- 999 __
- $a ok $b bmc $g 765533 $s 629400
- BAS __
- $a 3
- BMC __
- $a 2010 $b 14 $c 2 $m Psychiatrie (Praha, Print) $x MED00011067 $d 80-84
- LZP __
- $b přidání abstraktu $a 2010-34/vtmv